Ignite Creation Date:
2025-12-25 @ 4:17 AM
Ignite Modification Date:
2026-02-24 @ 2:30 PM
Study NCT ID:
NCT02603120
Status:
COMPLETED
Last Update Posted:
2020-11-12
First Post:
2015-11-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed
Sponsor:
Gilead Sciences
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-11-11
Start Date Type:
ACTUAL
Primary Completion Date:
2017-05-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-10-23
Completion Date Type:
ACTUAL
First Submit Date:
2015-11-10
First Submit QC Date:
None
Study First Post Date:
2015-11-11
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-05-01
Results First Submit QC Date:
None
Results First Post Date:
2018-07-23
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-10-22
Last Update Post Date:
2020-11-12
Last Update Post Date Type:
ACTUAL